Cardiovascular Health
Cardiovascular peptide applications span from FDA-approved agents (semaglutide for MACE reduction, oxytocin for obstetric use) to mitochondrial cardioprotection (SS-31) and emerging RAS-targeting peptides (Angiotensin 1-7). The GLP-1 class has the strongest cardiovascular evidence.
Relevant Peptides
SELECT trial: 20% MACE reduction in non-diabetic overweight patients.
SURPASS-CVOT: CV outcomes confirmation.
Phase II for heart failure; mitochondrial protection.
ACE2 pathway; cardiovascular and anti-fibrotic human trials.
Russian 25-year observational cardiac data.
Russian vascular bioregulator.
Novel RAS peptide; animal cardiovascular data.
Direct CD36-mediated cardioprotection in animals.
GLP-1 Class: The Cardiovascular Evidence Standard
The GLP-1 drug class now has the strongest cardiovascular evidence of any drug class developed for metabolic disease. The SELECT trial (2024) showing semaglutide reducing cardiovascular events in non-diabetic, overweight patients marked a fundamental shift in how obesity is viewed as a cardiovascular risk factor.
Mitochondrial Cardioprotection
SS-31’s Phase II data for heart failure addresses a distinct mechanism from GLP-1 — mitochondrial energy production efficiency. These are complementary rather than competitive approaches.
Stay current on peptide evidence
Weekly regulatory updates and study breakdowns. Free.